OakChart

BioAffinity Technologies Inc

BIAFHealthcare·Diagnostics & Research·USA·Nano·NASD·Nov 11 • 3:59 PM ET

2.42+0.03 (1.46%)
2026-11-12 01:43 CET
Market cap
4.41 USD m
Revenue, TTM
5.53 USD m
Net income, TTM
-15.41 USD m
Free cash flow, TTM
-13.03 USD m
EPS diluted, TTM
-38.13
P/E
-
Compare

Price

BIAF against its 20, 50 and 200-day averages
2050200earnings
0.0020.0040.0023.2M46.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BIAFclose 2.4320-day 3.0450-day 5.72200-day 18.552.43

97.0% under the 52-week high of 80.70 on 23 Mar 2026. 52-week low 2.23 on 11 Nov 2026. Last 15 sessions, 67.3% high to low

Volume 0.02× normal · the line is the 50-bar volume average

Profile

BIAF
52-week range, 0% of the way up
2.2580.70

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.

Employees57
IPOSep 01, 2022
Beta-0.99
ATR, 14d0.56
Rel volume0.02
Short float2.95%
Insider own0.82%
Inst own3.72%

Snapshot

6 groups

Valuation

Index-
Market Cap4.41M
Enterprise Value3.36M
Income-15.41M
Sales5.53M
Book/sh3.36
Cash/sh1.40
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees57
IPOSep 01, 2022

Ratios

P/E-
Forward P/E-
PEG-
P/S0.80
P/B0.72
P/C1.73
P/FCF-
EV/EBITDA-
EV/Sales0.61
Quick Ratio1.47
Current Ratio1.51
Debt/Eq0.38
LT Debt/Eq0.28
Option/ShortNo / Yes

Earnings

EPS (ttm)-38.13
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y45.79% 21.77%
Sales past 3/5Y986.60% -
EPS Y/Y TTM87.82%
Sales Y/Y TTM-18.47%
EPS Q/Q91.71%
Sales Q/Q-25.99%
EarningsNov 06 AMC
EPS/Sales Surpr.- -

Ownership

Insider Own0.82%
Insider Trans0.00%
Inst Own3.72%
Inst Trans6.08%
ROA-161.37%
ROE-240.48%
ROIC-306.97%
Gross Margin20.41%
Oper. Margin-246.14%
Profit Margin-278.93%
SMA20-20.19%
SMA50-57.61%
SMA200-86.93%
Trades-

Technical

Shs Outstand1.82M
Shs Float1.81M
Short Float2.95%
Short Ratio0.01
Short Interest0.05M
52W High80.70 -97.00%
52W Low2.25 7.78%
Volatility13.72% 11.62%
ATR (14)0.56
RSI (14)34.04
Beta-0.99
Rel Volume0.02
Avg Volume3.67M
Volume76,436

Performance

Perf Week-17.24%
Perf Month-33.10%
Perf Quarter-57.79%
Perf Half Y-91.45%
Perf YTD-86.30%
Perf Year-92.52%
Perf 3Y-99.63%
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price2700.00
Prev Close2.39
Price2.42
Change %1.46%

Peers

Mkt cap
TickerCompanyMkt cap
BDSXBiodesix Inc112.22M
VCYTVeracyte Inc2.03B
ADVBAdvanced Biomed Inc3.84M
MDXHMDxHealth SA13.98M
PRPOPrecipio Inc44.40M
GHGuardant Health Inc20.94B
IMDXInsight Molecular Diagnostics Inc78.21M
LUCDLucid Diagnostics Inc77.52M
XGNExagen Inc121.98M
QTRXQuanterix Corp143.39M

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 100

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-06-5.890--72.0001.07--
2026Q22026-08-07-9.600--9.6601.51--
2026Q12026-05-08-12.150--12.1161.35--
2025Q32025-11-14-71.100-40.500-71.0521.451.411
2025Q22025-08-14-76.500-45.000-76.0731.271.511
2025Q12025-05-15-72.000-72.000-73.6381.852.111
2024Q42025-03-31-85.500-63.000-92.3092.202.421
2024Q32024-11-14-72.000-67.500-72.6572.352.541
2024Q22024-08-14-85.500-76.500-83.3812.402.451
2024Q12024-05-15-94.500-85.500-89.0332.412.001
2023Q42024-04-01-121.5-90.000-115.512.201.801
2023Q32023-11-14-117-81.000-118.540.300.101
2023Q22023-08-14-90.000-58.500-91.9040.020.001
2023Q12023-05-15-81.000--81.7880.92--
2022Q32022-12-12-526.5--264.50.00--
2026Q4---27.000--2.221

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2022FY-814.5-873-815.64.800.00
2023FY-409.5-378-408.312.502.10
2024FY-337.5-310.5-335.59.369.57
2025FY-129.9--337.56.16-
2026FY--121.5--7.31

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2025-11-141002.222.222.22
2026Q4S2025-11-111002.222.222.22
2026Q4S2025-11-101002.222.222.22
2026Q4S2025-11-091002.222.222.22
2026Q4S2025-11-081002.222.222.22
2026Q4S2025-11-071002.222.222.22
2026Q4S2025-11-061002.222.222.22
2026Q4R2025-11-14100-27.00-27.00-27.00
2026Q4R2025-11-11100-27.00-27.00-27.00
2026Q4R2025-11-10100-27.00-27.00-27.00
2026Q4R2025-11-09100-27.00-27.00-27.00
2026Q4R2025-11-08100-27.00-27.00-27.00
2026Q4R2025-11-07100-27.00-27.00-27.00
2026Q4R2025-11-06100-27.00-27.00-27.00

Estimate history

EPS, annual-201.744-443.363-385.884-815.598-408.308-335.498-129.945-38.1253
Period2019202020212022202320242025TTM
EPS, quarterly-72.657-92.309-73.638-76.073-71.052-10.461-12.116-9.66-5.888
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000.0052.5329.3626.1625.53
Period2019202020212022202320242025TTM
Sales, quarterly2.352.2081.8541.2691.4461.5931.3521.5111.07
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.0160.0160.0160.0190.0210.0350.31.167
Period2019202020212022202320242025MRQ
Shares, quarterly0.030.0350.0410.0630.2310.30.30.4521.167
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue5.536.169.362.530.000.000.000.00
Cost of Goods Sold Incl. D&A4.404.736.591.990.010.000.020.04
Gross Profit1.131.432.770.54-0.01-0.00-0.02-0.04
Selling, General and Administrative Excl. Other14.7312.0011.738.524.012.202.583.05
Research and Development2.832.091.781.721.291.331.611.85
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-13.60-10.57-8.95-7.97-4.01-2.21-2.60-3.09
Interest Expense0.050.040.090.042.531.000.380.21
Unusual Expense-3.810.000.001.653.124.280.00
Net Income Before Taxes-15.41-14.87-9.03-7.92-8.15-6.32-7.27-3.30
Income Taxes0.000.040.010.020.000.000.000.00
Consolidated Net Income-15.41-14.91-9.04-7.94-8.15-6.33-7.27-3.31
Net Income From Continuing Operations-15.41-14.91-9.04-7.94-8.15-6.33-7.27-3.31
Net Income-15.41-14.91-9.04-7.94-8.15-6.33-7.27-3.31
EPS (Recurring)-17.19-106.70-335.50-408.31-699.75-252.83-260.60-201.74
EPS (Basic, Before Extraordinaries)-38.13-129.95-335.50-408.31-815.60-385.88-443.36-201.74
EPS (Diluted)-38.13-129.95-335.50-408.31-815.60-385.88-443.36-201.74
EBITDA-13.23-10.07-8.35-7.72-4.00-2.20-2.58-3.05
Non-Operating Income (Expense)-0.01-0.440.020.090.050.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.990.530.780.590.200.030.200.33
Price To Sales Ratio1.060.331.185.081,498.72---
Gross Margin20.4123.2129.6221.40-121.72---
Operating Margin-246.14-171.58-95.64-314.84-83,511.51---
Net Margin-278.93-241.96-96.56-313.41-169,771.25---
Shares Outstanding1.170.300.030.020.020.020.020.02
Market Capitalization4.414.3514.1713.5513.3913.39--

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue1.071.511.351.591.451.271.852.21
Cost of Goods Sold Incl. D&A1.181.151.041.021.061.131.521.72
Gross Profit-0.110.360.310.570.390.140.330.49
Selling, General and Administrative Excl. Other3.403.703.933.712.682.662.963.44
Research and Development0.640.840.680.670.470.440.510.52
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.51-3.33-3.62-3.14-2.29-2.52-2.63-2.95
Interest Expense0.010.010.010.010.010.010.020.03
Unusual Expense1.750.000.00-2.751.060.000.00
Net Income Before Taxes-5.28-3.37-3.63-3.13-5.05-4.03-2.65-2.97
Income Taxes0.000.000.000.000.000.030.010.00
Consolidated Net Income-5.28-3.37-3.63-3.14-5.05-4.06-2.66-2.97
Net Income From Continuing Operations-5.28-3.37-3.63-3.14-5.05-4.06-2.66-2.97
Net Income-5.28-3.37-3.63-3.14-5.05-4.06-2.66-2.97
EPS (Recurring)-4.52-9.66-12.12-10.46-44.00-62.13-73.64-92.31
EPS (Basic, Before Extraordinaries)-5.89-9.66-12.12-10.46-71.05-76.07-73.64-92.31
EPS (Diluted)-5.89-9.66-12.12-10.46-71.05-76.07-73.64-92.31
EBITDA-3.44-3.27-3.50-3.01-2.18-2.40-2.47-2.79
Non-Operating Income (Expense)-0.01-0.020.000.02-0.00-0.44-0.010.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.140.780.010.050.050.170.260.18
Price To Sales Ratio1.060.723.040.860.470.900.481.41
Gross Margin-10.3523.9122.8235.7227.0011.0017.8722.28
Operating Margin-328.01-220.77-267.62-196.94-158.56-198.16-141.73-133.47
Net Margin-493.05-222.83-268.63-196.98-349.30-319.88-143.53-134.40
Shares Outstanding1.170.450.300.300.230.060.040.03
Market Capitalization4.415.5117.235.3110.268.174.7514.17

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments6.451.112.8211.411.360.080.58
Short Term Receivables0.541.140.810.010.000.000.00
Inventories0.050.030.020.010.000.000.00
Other Current Assets0.520.420.320.530.080.030.04
Total Current Assets7.572.703.9711.961.450.120.62
Net Property, Plant & Equipment1.261.621.990.210.000.010.03
Total Investments and Advances0.000.000.000.000.000.000.00
Intangible Assets2.122.182.24----
Other Assets0.010.020.020.010.000.020.01
Total Assets10.966.518.2212.181.450.150.66
Short Term Debt Incl. Current Port. of LT Debt0.380.690.460.2511.209.954.01
Accounts Payable0.760.990.600.350.230.190.10
Other Current Liabilities1.761.421.180.541.600.980.58
Total Current Liabilities2.913.102.251.1413.0411.124.69
Long Term Debt0.780.811.120.000.160.050.00
Provision for Risks Charges0.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.00
Total Liabilities3.683.913.371.1413.2011.174.69
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value1E-060.000.000.004.044.044.04
Common Equity7.282.604.8611.04-15.79-15.07-8.08
Total Shareholders Equity7.282.604.8611.04-11.75-11.03-4.04
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity7.282.604.8611.04-11.75-11.03-4.04
Total Liabilities & Stockholders Equity10.966.518.2212.181.450.150.66
Book Value Per Share24.2775.17232.57592.93-963.16-919.38-492.84
Tangible Book Value Per Share17.1912.20125.37592.93-963.16-919.38-492.84
Full-Time Employees5757751411--
Price to Book Ratio0.715.451.941.061.06--
Return on Assets-170.65-122.70-77.80-119.60-791.34-1,807.21-
Return on Equity-301.83-242.44-99.84----
Return on Invested Capital-185.11-265.19-132.87-73.84---
Quick Ratio2.580.861.7610.500.110.010.13
Current Ratio2.600.871.7710.500.110.010.13

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-15.41-14.91-9.04-7.94-8.15-6.33-7.27-3.31
Depreciation0.370.500.610.250.010.000.020.04
Other Funds (Non Cash)2.324.480.990.753.903.464.560.45
Funds from Operations-12.73-9.92-7.44-6.94-4.24-2.86-2.69-2.81
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-0.130.590.180.900.110.630.480.32
Cash from Operating Activities-12.86-9.33-7.26-6.04-4.13-2.23-2.21-2.49
Capital Expenditures-0.17-0.06-0.08-0.02-0.220.00-0.00-0.01
Net Assets From Acquisitions0.000.000.00-2.190.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.17-0.06-0.08-2.21-0.220.00-0.00-0.01
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock7.2315.105.800.0013.820.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock7.2315.105.800.0013.820.000.000.00
Proceedsfrom Stock Options7.2310.294.350.006.030.000.000.00
Issuance or Reduction of Debt, Net-0.19-0.37-0.17-0.340.583.511.722.33
Change in Long Term Debt-0.20-0.37-0.36-0.090.000.000.000.00
Issuance of Long Term Debt0.030.000.000.000.000.000.000.00
Reduction of Long Term Debt-0.24-0.37-0.36-0.090.000.000.000.00
Net Financing Active Other Cash Flow0.880.000.000.00-0.000.000.000.00
Other Financing Activities Uses0.880.000.000.00-0.000.000.000.00
Cash from Financing Activities7.9114.735.63-0.3414.403.511.722.33
Net Change in Cash-5.125.34-1.72-8.5910.051.28-0.50-0.17
Free Cash Flow-13.03-9.39-7.34-6.06-4.35-2.23-2.21-2.50
Preferred Dividends (Cash Flow)--0.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments2.552.433.106.457.670.80
Short Term Receivables0.740.890.690.540.450.42
Inventories0.110.080.080.050.040.04
Other Current Assets0.430.460.480.520.460.40
Total Current Assets3.833.874.347.578.611.67
Net Property, Plant & Equipment1.631.651.481.260.780.92
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets2.082.092.112.122.142.15
Other Assets0.020.020.010.010.010.01
Total Assets7.557.627.9510.9611.554.75
Short Term Debt Incl. Current Port. of LT Debt0.390.270.280.380.400.35
Accounts Payable0.950.970.840.760.941.17
Other Current Liabilities1.191.452.071.761.021.07
Total Current Liabilities2.532.683.182.912.362.59
Long Term Debt1.111.171.100.780.280.32
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.003.97
Total Liabilities3.643.854.283.682.646.89
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value1E-061E-061E-061E-061E-060.00
Common Equity3.913.773.667.288.90-2.14
Total Shareholders Equity3.913.773.667.288.90-2.14
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity3.913.773.667.288.90-2.14
Total Liabilities & Stockholders Equity7.557.627.9510.9611.554.75
Book Value Per Share3.368.3312.2124.2738.52-33.78
Tangible Book Value Per Share1.573.715.1817.1929.28-67.78
Full-Time Employees---57--
Price to Book Ratio0.721.464.710.731.15-3.83
Return on Assets-161.37-245.51-235.39-170.65-162.88-204.93
Return on Equity-240.48-1,860.15-622.65-301.83-245.18-1,802.45
Return on Invested Capital-105.11-68.16-76.27-38.95-54.98-
Quick Ratio1.471.411.342.583.640.63
Current Ratio1.511.441.362.603.650.64

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-5.28-3.37-3.63-3.14-5.05-4.06
Depreciation0.070.060.110.120.110.11
Other Funds (Non Cash)1.450.780.010.072.811.27
Funds from Operations-3.76-2.52-3.50-2.95-2.12-2.67
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.11-0.680.270.39-0.360.03
Cash from Operating Activities-3.87-3.20-3.23-2.56-2.48-2.65
Capital Expenditures-0.08-0.09-0.01-1E-060.00-0.01
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.08-0.09-0.01-1E-060.00-0.01
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.00---0.000.00
Change in Capital Stock4.512.690.000.0310.723.19
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock4.512.690.000.0310.723.19
Proceedsfrom Stock Options4.512.690.000.037.462.80
Issuance or Reduction of Debt, Net0.10-0.07-0.12-0.110.04-0.17
Change in Long Term Debt0.10-0.11-0.08-0.12-0.06-0.09
Issuance of Long Term Debt0.030.000.000.000.000.00
Reduction of Long Term Debt0.07-0.11-0.08-0.12-0.06-0.09
Net Financing Active Other Cash Flow-0.540.000.001.42-1.420.00
Other Financing Activities Uses-0.540.000.001.42-1.420.00
Cash from Financing Activities4.072.62-0.121.349.343.02
Net Change in Cash0.12-0.67-3.35-1.226.870.36
Free Cash Flow-3.95-3.29-3.23-2.56-2.48-2.66

Revenue breakdown

Diagnostic Research And Development2024: 8.65K 2025: 577
Laboratory Services2024: 9.35M 2025: 6.16M
United States2024: 9.36M 2025: 6.16M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.21%0.1M1.3M3.67M
2026-10-155.25%0.1M1.3M3.65M
2026-09-3010.04%0.1M1.2M3.11M
2026-09-156.19%0.1M1.2M2.55M
2026-08-317.58%0.0M0.6M218.01K
2026-08-142.50%0.0M0.5M26.28K
2026-07-315.38%0.0M0.4M25.39K
2026-07-158.59%0.0M0.4M28.58K
2026-06-3013.43%0.1M0.4M41.58K
2026-06-158.27%0.0M0.3M292.62K
2026-05-2910.14%0.0M0.3M573.71K
2026-05-1511.25%0.0M0.3M575.89K
2026-04-3015.55%0.0M0.3M584.67K
2026-04-1511.86%0.0M0.3M589.13K
2026-03-3112.46%0.0M0.3M570.67K
2026-03-1312.31%0.0M0.3M296.95K
2026-02-275.09%0.0M0.3M9.62K
2026-02-132.42%0.0M0.3M6.98K
2026-01-300.91%0.0M0.3M5.85K
2026-01-150.93%0.0M0.3M29.96K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-068-KCurrent report2026-11-06SEC
2026-11-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-03424B5SEC
2026-11-02424B5SEC
2026-10-298-KCurrent report2026-10-29SEC
2026-10-23DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-23SEC
2026-10-158-KCurrent report2026-10-15SEC
2026-10-138-KCurrent report2026-10-13SEC
2026-10-13PRER14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-10-098-KCurrent report2026-10-08SEC
2026-10-09424B5SEC
2026-10-09424B5SEC
2026-10-088-KCurrent report2026-10-08SEC
2026-10-068-KCurrent report2026-10-06SEC
2026-09-308-KCurrent report2026-09-30SEC
2026-09-29PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-29SEC
2026-09-228-KCurrent report2026-09-22SEC
2026-09-178-KCurrent report2026-09-17SEC
2026-09-118-KCurrent report2026-09-11SEC
2026-09-098-KCurrent report2026-09-08SEC
2026-09-08424B3SEC
2026-09-04EFFECTEffectiveness filing by commission orderSEC
2026-09-038-KCurrent report2026-09-03SEC
2026-09-03S-3/ASEC
2026-09-018-KCurrent report2026-09-01SEC
2026-08-27S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-208-KCurrent report2026-08-20SEC
2026-08-188-KCurrent report2026-08-18SEC
2026-08-148-KCurrent report2026-08-12SEC
2026-08-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
SABBY MANAGEMENT, LLC8.06%
BlackRock, Inc.2.18%
VANGUARD CAPITAL MANAGEMENT LLC1.22%
GEODE CAPITAL MANAGEMENT, LLC1.12%
J. Safra Sarasin Holding AG0.94%
Allworth Financial LP0.86%
VANGUARD FIDUCIARY TRUST CO0.69%
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.59%
JANE STREET GROUP, LLC0.59%
STATE STREET CORP0.53%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND1.22%
Fidelity Extended Market Index Fund0.28%
U.S. SMALL CAP PORTFOLIO0.24%
Dimensional U.S. Small Cap ETF0.14%
U.S. MICRO CAP PORTFOLIO0.09%
Fidelity Total Market Index Fund0.09%
Fidelity Series Total Market Index Fund0.07%
Fidelity Nasdaq Composite Index Fund0.03%

OakChart. BIAF. Cached 15 minutes.

Some panels did not load: ratings, insider.